FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985493306> ?p ?o ?g. }

• W1985493306 abstract "Abstract Background The aim of this study was to assess whether two-years treatment with Pirfenidone influences necroinflammation, fibrosis and steatosis, serum levels of TGF-β1, IL-6, TNF-α and CB1 and CB2 gene expression, in patients with chronic hepatitis C (CHC). Methods Twenty-eight patients out of 34 with CHC virus infection were enrolled in the study and received Pirfenidone (1200 mg/day) for 24 months. Six patients dropped out after 12 months of PFD. Liver biopsies and serum samples were obtained at the beginning and end of treatment. Modified HAI was calculated. CB1 and CB2 gene expression was correlated with fibrosis progression alongside with necroinflammation and steatosis. TGF-β1, IL-6, TNF-α and liver transaminases were measured in serum at two-months intervals. HCV genotype and viral load were also assessed. Quality of life was evaluated by SF36 questionnaires and the prognosis of disease was assessed with Child-Pugh score. The Wilcoxon test matched-pair signed ranks were used to analyze the outcomes. Results Intention to treat analyses were performed for biochemistry and clinical parameters. At the end of treatment, necroinflammation grading was reduced in an average of 3.2 points in 82% of patients (p < 0.05) and Ishak’s fibrosis stage decreased 2-points average in 67% of patients (p < 0.05). Steatosis decreased in 61% of patients. IL-6 and TGF-β1 serum levels decreased significantly in 93% and 67% of patients (p < 0.05), respectively, while TNF-α diminished in 47% of patients. ALT and AST tended to normalize in 81% of patients; CB2 mRNA levels increased in 86% and CB1 expression diminished in 29% of patients. Both, quality of life and Child-Pugh score improvements were reported in all patients. Conclusions Pirfenidone for two years benefits CHC patients and improves inflammation, fibrosis and steatosis in higher number of patients as previously shown for 12-months treatment with PFD. Additionally, PFD improved TGFβ1 and IL-6 levels and diminished liver expression of anti-fibrogenic receptor CB2. Trial registration ClinicalTrials.gov identifier: NCT02161952 . Protocol Registration Date: 06/11/2014." @default.
• W1985493306 created "2016-06-24" @default.
• W1985493306 creator A5019759526 @default.
• W1985493306 creator A5020802405 @default.
• W1985493306 creator A5048985625 @default.
• W1985493306 creator A5051830216 @default.
• W1985493306 creator A5084104543 @default.
• W1985493306 creator A5085501737 @default.
• W1985493306 creator A5086577347 @default.
• W1985493306 creator A5088649127 @default.
• W1985493306 date "2014-07-27" @default.
• W1985493306 modified "2023-10-09" @default.
• W1985493306 title "Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C" @default.
• W1985493306 cites W183377719 @default.
• W1985493306 cites W1906073977 @default.
• W1985493306 cites W1965854265 @default.
• W1985493306 cites W1967973854 @default.
• W1985493306 cites W1973867127 @default.
• W1985493306 cites W1976110218 @default.
• W1985493306 cites W1981900811 @default.
• W1985493306 cites W1999924323 @default.
• W1985493306 cites W2001427377 @default.
• W1985493306 cites W2024523210 @default.
• W1985493306 cites W2051124211 @default.
• W1985493306 cites W2063072396 @default.
• W1985493306 cites W2064590565 @default.
• W1985493306 cites W2069243984 @default.
• W1985493306 cites W2077806739 @default.
• W1985493306 cites W2083890832 @default.
• W1985493306 cites W2087275438 @default.
• W1985493306 cites W2088876699 @default.
• W1985493306 cites W2107277218 @default.
• W1985493306 cites W2115080342 @default.
• W1985493306 cites W2118218191 @default.
• W1985493306 cites W2120822890 @default.
• W1985493306 cites W2122664567 @default.
• W1985493306 cites W2139840825 @default.
• W1985493306 cites W2141214317 @default.
• W1985493306 cites W2145623055 @default.
• W1985493306 cites W2145744172 @default.
• W1985493306 cites W2150306938 @default.
• W1985493306 cites W2151429631 @default.
• W1985493306 cites W2155681713 @default.
• W1985493306 cites W2158129157 @default.
• W1985493306 cites W2163346237 @default.
• W1985493306 cites W2168666423 @default.
• W1985493306 cites W2171324990 @default.
• W1985493306 cites W2171583239 @default.
• W1985493306 cites W2171713163 @default.
• W1985493306 doi "https://doi.org/10.1186/1471-230x-14-131" @default.
• W1985493306 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4236537" @default.
• W1985493306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25064094" @default.
• W1985493306 hasPublicationYear "2014" @default.
• W1985493306 type Work @default.
• W1985493306 sameAs 1985493306 @default.
• W1985493306 citedByCount "64" @default.
• W1985493306 countsByYear W19854933062014 @default.
• W1985493306 countsByYear W19854933062015 @default.
• W1985493306 countsByYear W19854933062016 @default.
• W1985493306 countsByYear W19854933062017 @default.
• W1985493306 countsByYear W19854933062018 @default.
• W1985493306 countsByYear W19854933062019 @default.
• W1985493306 countsByYear W19854933062020 @default.
• W1985493306 countsByYear W19854933062021 @default.
• W1985493306 countsByYear W19854933062022 @default.
• W1985493306 countsByYear W19854933062023 @default.
• W1985493306 crossrefType "journal-article" @default.
• W1985493306 hasAuthorship W1985493306A5019759526 @default.
• W1985493306 hasAuthorship W1985493306A5020802405 @default.
• W1985493306 hasAuthorship W1985493306A5048985625 @default.
• W1985493306 hasAuthorship W1985493306A5051830216 @default.
• W1985493306 hasAuthorship W1985493306A5084104543 @default.
• W1985493306 hasAuthorship W1985493306A5085501737 @default.
• W1985493306 hasAuthorship W1985493306A5086577347 @default.
• W1985493306 hasAuthorship W1985493306A5088649127 @default.
• W1985493306 hasBestOaLocation W19854933061 @default.
• W1985493306 hasConcept C126322002 @default.
• W1985493306 hasConcept C2775934546 @default.
• W1985493306 hasConcept C2776175330 @default.
• W1985493306 hasConcept C2777714996 @default.
• W1985493306 hasConcept C2777766500 @default.
• W1985493306 hasConcept C2778341716 @default.
• W1985493306 hasConcept C2779832356 @default.
• W1985493306 hasConcept C2780559512 @default.
• W1985493306 hasConcept C41260117 @default.
• W1985493306 hasConcept C71924100 @default.
• W1985493306 hasConcept C90924648 @default.
• W1985493306 hasConceptScore W1985493306C126322002 @default.
• W1985493306 hasConceptScore W1985493306C2775934546 @default.
• W1985493306 hasConceptScore W1985493306C2776175330 @default.
• W1985493306 hasConceptScore W1985493306C2777714996 @default.
• W1985493306 hasConceptScore W1985493306C2777766500 @default.
• W1985493306 hasConceptScore W1985493306C2778341716 @default.
• W1985493306 hasConceptScore W1985493306C2779832356 @default.
• W1985493306 hasConceptScore W1985493306C2780559512 @default.
• W1985493306 hasConceptScore W1985493306C41260117 @default.
• W1985493306 hasConceptScore W1985493306C71924100 @default.
• W1985493306 hasConceptScore W1985493306C90924648 @default.
• W1985493306 hasIssue "1" @default.
• W1985493306 hasLocation W19854933061 @default.

• next